Drugs / TNB-738
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05215912 | Apr 2022 → May 2023 | — | TeneoFour Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNB-738 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05215912 ↗ |
| Action | Inhibit | “used to inhibit human CD38 enzyme” NCT05215912 ↗ |
| Target | CD38 | “TNB-738 is a fully human bispecific antibody used to inhibit human CD38 enzyme.” NCT05215912 ↗ |